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Abstract
In the phase III study RESONATE, ibrutinib reduced the risk of progression and improved overall survival versus
ofatumumab in previously treated patients with CLL/SLL. In this novel analysis of patient well-being including
patient-reported outcomes, ibrutinib reduced disease burden while preserving parameters of hematologic and
immunologic function in RESONATE. These results suggest that ibrutinib can improve quality of life while
prolonging survival.
Background: Ibrutinib compared with ofatumumab signiﬁcantly improves progression-free and overall survival in
patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Patients and
Methods:Measures of well-being were assessed in RESONATE, where previously treated patients with CLL/SLL were
randomized to receive ibrutinib 420 mg/day (n ¼ 195) or ofatumumab (n ¼ 196) for up to 24 weeks. Endpoints included
hematologic function, Functional Assessment of Chronic Illness TherapyeFatigue (FACIT-F), disease-related symp-
toms, European Organization for Research and Treatment of Cancer Quality of Life Questionnaires Core 30 (EORTC
QLQ-C30), and medical resource utilization. Results: With up to 24 months’ follow-up (median, 16.4 months), 79% of
cytopenic patients showed sustained hematologic improvement (82% with improved platelet count, 69% with1Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY
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Patient Well-being With Ibrutinib in R/R CLLimproved hemoglobin) on ibrutinib versus 43% on ofatumumab (P < .0001). Higher rates of clinically meaningful
improvement were demonstrated with ibrutinib versus ofatumumab for FACIT-F and EORTC global health. Greater
improvement was observed in disease-related weight loss, fatigue, night sweats, and abdominal discomfort
with ibrutinib versus ofatumumab. Hospitalizations in the ﬁrst 30 days occurred less frequently with ibrutinib than
ofatumumab (0.087 vs. 0.184 events/patient; P ¼ .0198). New-onset diarrhea was infrequent with ibrutinib after the
ﬁrst 6 months (47% at 6 months vs. 5% at 12-18 months). With ibrutinib, grade  3 hypertension occurred in 6%,
grade  3 atrial ﬁbrillation in 4%, major hemorrhage in 2%, and tumor lysis syndrome in 1% of patients. Conclusion:
Ibrutinib led to signiﬁcant improvements in hematologic function and disease symptomatology versus ofatumumab,
and can restore quality of life while prolonging survival in relapsed/refractory CLL/SLL.
Clinical Lymphoma, Myeloma & Leukemia, Vol. 18, No. 12, 803-13 ª 2018 The Authors. Published by Elsevier Inc. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Chronic lymphocytic leukemia (CLL) is a common leukemia in
the United States1; manifestations of progressive disease and in-
dications for treatment include lymphadenopathy, splenomegaly,
bone marrow failure (anemia, thrombocytopenia), and signiﬁcant
disease-related symptoms.2 CLL complications and toxicities asso-
ciated with therapy can profoundly impact quality of life (QoL) and
well-being, particularly in older patients.3,4 Patient-reported
outcome (PRO) scores of emotional well-being tend to be lower
in patients with CLL than in patients with other malignancies,4 and
studies have shown signiﬁcant QoL improvements with effective
CLL treatment including chemotherapy, as well as in prior small
non-randomized studies with ibrutinib.5-11
Ibrutinib, an oral, ﬁrst-in-class, once-daily inhibitor of Bruton’s
tyrosine kinase, has shown substantial single-agent efﬁcacy and
tolerability in CLL/small lymphocytic lymphoma (SLL).12-15 In the
phase III study (RESONATE) comparing ibrutinib with ofatu-
mumab in previously treated patients with CLL/SLL, ibrutinib
reduced risk of progression as assessed by an independent review
committee (IRC) by 78% and risk of death by 57% with a median
follow-up of 9.4 months at primary analysis.14 Measures of patient
well-being including parameters of hematologic and immunologic
function, and QoL are reported from the RESONATE study. These
data are the ﬁrst to show sustained improvements in PRO, hema-
tologic function, and disease symptoms associated with ibrutinib in
a randomized study.
Patients and Methods
Patients
Patients with CLL/SLL who had received  1 prior therapy and
had active disease with an indication for therapy per International
Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines
were enrolled.2 Eligibility criteria have been described previously.14
All patients provided written informed consent.
Study Design
Patients were randomized to once-daily oral ibrutinib (420 mg)
or intravenous ofatumumab as previously described.14 Ofatumu-
mab data beyond 6 months were limited by maximum treatment
duration (6 months) and a median progression-free survival (PFS) ofClinical Lymphoma, Myeloma & Leukemia December 20188.1 months,14 affecting the efﬁcacy and safety variables in this
updated analysis. Further, 122 patients randomized to ofatumumab
had crossed over to ibrutinib after disease progression (PD).
Study Endpoints
PFS, overall survival (OS), and overall response rate (ORR) have
been previously reported.2,14 Secondary efﬁcacy endpoints include
sustained hematologic improvement (see Supplemental Methods [in
the online version] for deﬁnition) in patients with cytopenia(s) at
baseline, and PRO as measured by Functional Assessment of
Chronic Illness Therapy-Fatigue (FACIT-F). FACIT-F is a vali-
dated instrument that assesses tiredness, weakness, and difﬁculty
conducting daily activities owing to fatigue. Scores range from 0 to
52, with high scores indicating less fatigue.16 A change in FACIT-F
score of  3 points17 was considered clinically meaningful. FACIT-
F forms and other PRO instruments were generally completed by
patients prior to any study procedures. Per protocol, patients were
not required to complete the questionnaire following PD/crossover
or after completing treatment if assigned to the ofatumumab arm.
Prespeciﬁed exploratory endpoints included improvement of
investigator-assessed disease-related symptoms (National Cancer
Institute Common Terminology Criteria for Adverse Events,
version 4.0 [CTCAE] grade decrease of  1 post-baseline, reported
for  2 consecutive assessments of weight loss, fatigue, fever, night
sweats, abdominal discomfort owing to splenomegaly, and/or
anorexia), PRO as measured by European Organization for
Research and Treatment of Cancer Quality of Life Questionnaires
Core 30 (EORTC QLQ-C30; clinically meaningful change deﬁned
as > 10 points18), and medical resource utilization associated with
therapy including number of hospitalizations, any blood product
transfusions (red blood cells, platelets, whole blood), and use of any
hematopoietic growth factors. Compliance rates for FACIT-F and
EORTC QLQ-C30 questionnaire completion were monitored (see
Supplemental Table 1 in the online version).
To evaluate disease burden, lymph nodes and splenic enlarge-
ment were quantiﬁed by IRC-assessed computed tomography;
reduction was deﬁned per iwCLL criteria.2 The effect of ibrutinib
versus ofatumumab on white blood cell count and differential was
evaluated over time. Lymphocyte subsets (B cells, T cells, natural
killer [NK] cells [see Supplemental Methods in the online version])
Jacqueline C. Barrientos et alwere evaluated by ﬂow cytometry for patients with baseline samples.
Serum immunoglobulin levels (IgA, IgG, IgM) were quantitated.
Adverse event (AE) severity was graded using CTCAE, except for
hematologic toxicities, which were graded based on iwCLL criteria.2
The treatment-emergent period for AE collection was deﬁned as the
time from the ﬁrst dose of study drug to 30 days after the last dose
of study drug or initiation of subsequent antineoplastic therapy,
whichever comes ﬁrst. Treatment-emergent AEs were summarized
by time to event onset and by prevalence. (See Supplemental
Methods in the online version, for details regarding statistical
methods used in the study.)
Results
Baseline Characteristics and Patient Disposition
As described previously, 391 patients with previously treated
CLL/SLL were randomized to ibrutinib (n ¼ 195; median 3 prior
therapies [range, 1-12]) or ofatumumab (n ¼ 196; median 2 prior
therapies [range, 1-13]).14 Baseline characteristics were balanced
across both treatment groups and have been previously published.14
In general, the enrolled population was elderly (over 20% of pa-
tients were aged  75 years), and comorbidities were common
(such as reduced creatinine clearance and cytopenias at baseline).
The median follow-up was 9.4 months at the time of primary
analysis. This analysis reﬂects data at a median follow-up of 15.0
months (16.4 for ibrutinib, 11.9 for ofatumumab; up to 24 months
maximum).
Sustained Hematologic Improvement
In cytopenic patients treated with ibrutinib, 69% showed sus-
tained improvement in hemoglobin, 82% in platelets, and 68% in
absolute neutrophil count, all of which were statistically signiﬁcant
versus changes with ofatumumab (Table 1). Of ibrutinib patients
with any baseline cytopenia, 79% showed sustained improvement
in blood counts with this longer follow-up compared with 69% at
the primary analysis, where it was signiﬁcantly higher versus ofa-
tumumab (43%; P < .0001). Figure 1A, B demonstrates early
improvement in median hemoglobin and platelet levels, respec-
tively, which were sustained during the ﬁrst 6 months in patients in
both treatment arms with baseline cytopenias, and through 16
months on the ibrutinib arm.Table 1 Baseline Cytopenias and Sustained Hematologic Improvem
Baseline Cytopenia(s)
Ibrutinib
(n [ 195)
Ofatum
(n [
Thrombocytopenia, n (%) 74 (38) 64 (33
Median platelet count,  109/L (range) 65.5 (20-99) 72 (23
Neutropenia, n (%) 41 (21) 38 (19
Median neutrophil count,  109/L (range) 1.1 (0.4-1.5) 1.1 (0.3
Anemia, n (%) 89 (46) 86 (44
Median hemoglobin, g/dL (range) 9.8 (6.5-11) 9.8 (6.2
Any cytopenia, n (%) 124 (64) 123 (63
aSustained improvement  56 days without transfusions or growth factors. Blood counts assessedPatient-Reported Outcomes
FACIT-F. Baseline FACIT-F scores for ibrutinib and ofatumu-
mab were similar (mean, 35.7 vs. 34.5, respectively). More patients
achieved clinically meaningful improvement in FACIT-F with
ibrutinib versus ofatumumab (56% vs. 43%; odds ratio [OR], 1.69;
P ¼ .0101); clinically meaningful improvement with ibrutinib was
sustained through 60 weeks of follow-up (Figure 1C).
EORTC QLQ-C30. At baseline, ibrutinib and ofatumumab
patients had similar mean scores for EORTC QLQ-C30 global
health status (60.0 vs. 58.3, respectively). Greater improvement in
global health status mean score was seen at 24 weeks with ibrutinib
versus ofatumumab (9.0 vs. 5.8, respectively) (see Supplemental
Table 2 in the online version). Of the 15 EORTC domains
assessed at baseline, nausea/vomiting, diarrhea, and constipation
had the lowest severity, and global health status had the highest
impairment. At week 24, patients treated with ibrutinib improved
on 13 (all but nausea/vomiting and diarrhea) versus 12 domains (all
but cognitive functioning, pain, or constipation) with ofatumumab
(see Supplemental Table 2 in the online version). A signiﬁcantly
greater proportion of patients on ibrutinib compared with ofatu-
mumab reported an improvement in cognitive functioning,
including concentration and recall (32% vs. 20%; P ¼ .008).
Overall, the mean change in scores from baseline to week 24 across
the EORTC QLQ-C30 domains appeared comparable between
treatment arms. An improvement in the EORTC Fatigue Subscale
score from baseline to week 24 was seen with ibrutinib (n ¼ 117;
median 11-point improvement), whereas no improvement was seen
with ofatumumab (n ¼ 87; median 0-point improvement).
Reduction in Disease Burden
Disease burden was assessed by independent review prior to
discontinuation for the primary analysis with 9.4 months median
follow-up, similar to the median PFS for the ofatumumab arm (8.1
months). At least a 50% reduction in lymph node size was observed
more frequently with patients on ibrutinib versus ofatumumab
(92% vs. 14%; P < .0001) (Figure 2A); the median time to
reduction was 2.6 versus 5.3 months with ibrutinib and ofatumu-
mab, respectively. Reduction in spleen size was more common in
ibrutinib-treated than ofatumumab-treated patients (85% vs. 54%;enta
Sustained Hematologic Improvement in Patients With
Speciﬁed Cytopenia(s) at Baseline, n/N (%)
umab
196) Ibrutinib Ofatumumab P Value
) 61/74 (82) 14/64 (22) < .0001
-100)
) 28/41 (68) 12/38 (32) .0011
-1.5)
) 61/89 (69) 32/86 (37) < .0001
-11)
) 98/124 (79) 53/123 (43) < .0001
by central laboratory.
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Figure 1 Change Over Time by Treatment Arm in Median Hgb Levels (A), Median Platelet Count (B), and Improvement in FACIT-F
Including Long-Term Extended Follow-Up (C)
Abbreviations: FACIT-F ¼ Functional Assessment of Chronic Illness Therapy-Fatigue; Hgb ¼ hemoglobin.
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806 -P < .0001) (Figure 2B); the median time to reduction was 2.6
months with both ibrutinib and ofatumumab. These improvements
are consistent with recently published updates to PFS and OS
showing continued beneﬁt for patients randomized to ibrutinib
(median follow-up 19 months: PFS, hazard ratio [HR], 0.106;
P < .0001; 18-month landmark OS, HR, 0.361; 95% conﬁdence
interval [CI], 0.208-0.628).14,19
Disease-Related Symptoms and Medical Resource
Utilization
Consistent with ﬁndings at the primary analysis, improvement in
disease-related symptoms were assessed by investigators more
frequently with ibrutinib than with ofatumumab for weight loss
(100% vs. 87%), fatigue (79% vs. 64%), night sweats (89% vs.
77%), abdominal pain/discomfort (96% vs. 75%), and anorexia
(100% vs. 64%), but not fever (88% vs. 100%). Hospitalizations in
the ﬁrst 30 days occurred less frequently with ibrutinib than ofa-
tumumab (0.087 vs. 0.184 events/patient20; P ¼ .0198); however,
no signiﬁcant differences were observed through 6 months. Growth
factor usage after day 30 occurred slightly more frequently with
ofatumumab than ibrutinib (5%-9% vs. 2%-4% each month
through month 6, respectively). Transfusion rates with ibrutinibClinical Lymphoma, Myeloma & Leukemia December 2018and ofatumumab (30% vs. 24%) were not notably different
through 6 months.
White Blood Cell Count, Lymphocyte Counts, and Serum
Immunoglobulin Levels
In both arms, the white blood cell differential trended to normal
with an increase in the proportion of neutrophils and a decrease in
lymphocyte proportions versus baseline (see Supplemental
Figure 1A in the online version). In the ibrutinib arm, elevated
baseline absolute lymphocyte count (ALC) declined over time to a
median of 50% below baseline at 24 weeks and continued to
decrease to normal (< 4  109/L) at later time points (after the
expected initial transient increase with ibrutinib) (see Supplemental
Figure 1B, C in the online version). Supplemental Table 3 (in the
online version) shows distributions of peak ALC in ibrutinib-treated
patients relative to baseline ALC.
The primarily malignant B cell counts were stable with ibrutinib
and decreased with ofatumumab at week 12 (Figure 3 and
Supplemental Figure 2 [in the online version]). After week 12, B cell
counts in the ibrutinib arm also decreased signiﬁcantly over time,
with median count approaching the upper limit of normal at week
72. Median T cell (including CD3þ, CD4þ, and CD8þ subsets)
Figure 2 Reduction in Lymph Nodes (A) and Splenic Enlargementy (B) (Primary Analysis)
Sum of the products of multiple lymph nodes (as evaluated by computed tomography scans) or the longest diameter of one target lymph node. yPatients who experienced resolution of splenic
enlargement by IRC are considered to have 100% reduction.
Abbreviations: IRC ¼ independent review committee; NE ¼ not evaluable; PD ¼ progressive disease; PR ¼ partial response; PR-L ¼ PR with lymphocytosis; SD ¼ stable disease.
Jacqueline C. Barrientos et aland NK cell counts remained within the limits of normal
throughout testing, whereas the relative proportion of T cells
(including CD4þ and CD8þ subsets) and NK cells progressively
increased over time. For 57 patients with available baseline samples,
median counts for CD3þ and CD4þ T cells (but not CD8þ) and
NK cells were signiﬁcantly decreased at week 72, remaining above
the lower limits of normal (LLN). The median regulatory T cellcounts signiﬁcantly decreased over time on ibrutinib, dropping from
the upper limit of normal to the LLN (see Supplemental Figure 3 in
the online version).
Analysis of serum Immunoglobulin levels (excluding the 32%
and 22% of ibrutinib and ofatumumab patients on intravenous
Immunoglobulin replacement) showed a signiﬁcant increase in IgA
levels with ibrutinib, rising to the LLN at week 12, which wasClinical Lymphoma, Myeloma & Leukemia December 2018 - 807
Figure 3 Absolute Counts Over Time of CD3D (A), CD4D (B), CD8D (C), CD19D (D), and CD16/56D (E) Cells. ULN and LLN (3 109/L):
CD3D, 0.723-2.737; CD4D, 0.404-1.612; CD8D, 0.22-1.129; CD19D, 0.08-0.724; and CD16/56D, 0.084-0.724. In Each Chart,
ULN and LLN are Shown by Dashed Lines (With Axis Breaks); Only ULN is Shown for CD19D Cells
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808 -maintained through week 72. Median IgG levels were stable with
up to 1.4 years on ibrutinib, rising to the LLN at week 72. Median
IgM level changes were nonsigniﬁcant and varied over time from
just above to just below the LLN from week 36 to week 60
(Figure 4). For those with baseline levels below the LLN, a similar
increase was observed for IgA without signiﬁcant decrement in IgG
or IgM over time (data not shown).
Adverse Events
Most AEs were grade 1 in severity. The most frequently observed
AEs among ibrutinib patients at any time were diarrhea (37% gradeClinical Lymphoma, Myeloma & Leukemia December 20181, 10% grade 2, 4% grade 3), fatigue (19% grade 1, 12% grade 2,
3% grade 3), and nausea (24% grade 1, 6% grade 2, 2% grade 3), of
which none were grade 4. Except for diarrhea (all grade), rates of
common AEs in the ﬁrst 6 months were similar between the
treatment arms (Figure 5A). New onset of these events was less
frequent after the ﬁrst 6 months such as diarrhea (all grades) rates,
which declined over time from 47% at 0 to 6 months to 5% at 12
to 18 months (Figure 5B).
With prolonged ibrutinib treatment, the most frequent grade 
3 AEs at any time were neutropenia (18%), pneumonia (11%),
hypertension (6%), and thrombocytopenia (6%). The incidences
Figure 4 Median Levels Over Time of IgA (A), IgG (B), and IgM (C). LLN for Baseline IgA, IgG, and IgM are 0.7 g/L, 5.65 g/L, and 0.4 g/L,
Respectively, and are Shown by Dashed Lines
Excluding patients on intravenous Ig.
Abbreviations: Ig ¼ immunoglobin; LLN ¼ lower limit of normal.
Jacqueline C. Barrientos et alof grade  3 infections and cytopenias were similar for ibrutinib
and ofatumumab during the ﬁrst 6 months of therapy
(Figure 5A). Except for hypertension, the incidences of other
frequent grade  3 AEs decreased or were similar over time
(Figure 5C). Prevalence of grade  3 infections at any time was
30% for ibrutinib and 20% for ofatumumab (see Supplemental
Figure 4 in the online version). Exposure-adjusted all-grade
infection rate with ibrutinib versus ofatumumab was 14.7 versus
18.4 per 100 patient-months (grade  3 was 2.5 vs. 5.7,
respectively). Upper respiratory tract infection was the most
common all-grade infection for both the overall ibrutinib cohort
(24%) and those with compromised Ig status at baseline (25% for
IgA < LLN, 26% for IgG < LLN).
Atrial ﬁbrillation occurred at any time in 13 (7%) patients,
including grade  3 in 7 (4%) patients, resolving in 6 of 7 patients
and leading to ibrutinib discontinuation in 1 patient, who was
subsequently noted to have PD; the majority of grade  3 atrial
ﬁbrillation events were reported in the ﬁrst 6 months of ibrutinib
therapy. Major hemorrhage occurred in 4 patients (2%): grade 2
subdural hematoma, grade 3 post-procedural hemorrhage, grade 3
spontaneous hematoma, and grade 4 subdural hematoma (see
Supplemental Table 4 in the online version). Tumor lysis syndrome
occurred 5 and 11 days after ibrutinib discontinuation in 2 patientswith PD (study days 534 and 242, respectively) who had not yet
started any next line therapy for CLL.
At a median treatment duration of 16 months for ibrutinib versus
5 months for ofatumumab, 13 ibrutinib patients and 7 ofatumu-
mab patients discontinued study drug primarily due to AEs. In
total, 23 and 16 patients, respectively, had AEs associated with
discontinuation, most frequently pneumonia; among patients who
discontinued ibrutinib due to AEs, longer duration of therapy ap-
pears to be associated with increased time to progression (see
Supplemental Table 5 in the online version). AEs leading to ibru-
tinib discontinuation occurred in 12 of 195, 9 of 172, 1 of 159, and
1 of 39 patients at 0 to 6, 7 to 12, 13 to 18, and 19 to 24 months,
respectively. AEs leading to ibrutinib dose reduction occurred in 7
of 195, 4 of 172, and 2 of 159 patients at 0 to 6, 7 to 12, and 13 to
18 months, respectively.
Discussion
Ibrutinib is a selective ﬁrst-in-class irreversible inhibitor of Bru-
ton’s agammaglobulinemia tyrosine kinase with an important role in
multiple cellular functions including B-cell antigen receptor
signaling. A high frequency of durable responses and acceptable
safety associated with ibrutinib in the previously treated population
with CLL has been demonstrated in the RESONATE study withClinical Lymphoma, Myeloma & Leukemia December 2018 - 809
Figure 5 Incidence of Common (‡ 20% for all Grade, ‡ 3% for Grade ‡ 3 at Any Time) Treatment-Emergent Adverse Events that
Occurred in the First 6 Months of Treatment in the Ibrutinib and Ofatumumab Arms (A), for all Grades by Time to Event Onset
(B), and for Grades ‡ 3 by Time to Event Onset in the Ibrutinib Arm (C). New Events are Presented Only During the Period of
Time Where Event Began. Note, No Grade ‡ 3 Events Started at > 18 Months
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810 -enhanced PFS, OS, and ORR as compared with ofatumumab,
including in high-risk subgroups.14,19 This report demonstrates that
in addition to its known efﬁcacy, prolonged administration of
ibrutinib confers patients additional beneﬁts as assessed by multiple
measures of well-being, including preservation of parameters ofClinical Lymphoma, Myeloma & Leukemia December 2018hematologic and immunologic function. At a median of 16.4
months follow-up, the present data are among the ﬁrst reports from
a randomized phase III study to demonstrate signiﬁcant improve-
ment in hematologic and immunologic parameters in parallel with
QoL improvements. In the majority of patients with baseline
Jacqueline C. Barrientos et alcytopenias, ibrutinib led to early and sustained platelet and hemo-
globin improvements (82% and 69%, respectively), which were
markedly better than for the patients randomized to ofatumumab.
With up to 2 years of follow-up, the positive hematologic effects
of ibrutinib resulted in sustained normalization of hemoglobin in
69% and of platelet count in 82% of patients with baseline anemia
and thrombocytopenia, respectively. Transient increase followed by
sustained decrease in percentage of lymphocytes over time is
expected given the known pharmacodynamic ‘redistribution’ phe-
nomenon of B-cell receptor inhibitor treatment-related lymphocy-
tosis. Malignant B cell counts decreased dramatically with ibrutinib
and approached normal limits by week 72, and median CD4þ,
CD8þ, and NK cell counts remained within normal limits
throughout treatment. Reduction in regulatory T cell counts to the
LLN was observed in ibrutinib-treated patients consistent with
preclinical studies of ibrutinib and other clinical data sets.21-23
Future analyses discriminating normal from neoplastic B cells
would be beneﬁcial to ascertain any modulatory effects of ibrutinib.
An increase in IgA levels was also observed with ibrutinib over time,
without signiﬁcant decrement in IgG or IgM.
In a National Institutes of Health study of patients with
CLL  65 years of age or with TP53 aberration, the infection rate
overall was lower in treatment-naive (TN) versus relapsed/refractory
(R/R) patients, but rates declined over time in both TN and R/R
populations24; data that suggest clinically relevant improvement in
humoral immunity with ibrutinib treatment. In an integrated
analysis of patients from the RESONATE and RESONATE-2
(ibrutinib vs. chlorambucil in older patients with TN CLL/SLL)
trials, infection rates were also shown to decrease with time on
ibrutinib.25 Although the decreased incidence of various infections
over time seen during ibrutinib treatment in this and other reports
may reﬂect these positive hematologic effects on lymphocytes and
immunoglobulin levels, future detailed analyses of these infections
may be warranted, given recent descriptions of opportunistic
infections occurring during ibrutinib treatment.26,27
PROs, including health-related QoL, are increasingly assessed in
clinical trials as a measure of effectiveness and to help with decision-
making. Analysis of FACIT-F outcomes showed that a clinically
meaningful improvement from baseline was reached in < 24 weeks
with ibrutinib and ofatumumab, with mean improvement sustained
through 60 weeks of follow-up on ibrutinib. Similarly, fatigue was
improved as measured with the EORTC fatigue subscale PRO as
well as investigator-assessed disease-related symptoms. Additionally,
100% of patients treated with ibrutinib experienced improvements
in weight loss and anorexia. The magnitude of improvement (mean
change from baseline to week 24) in EORTC QLQ-C30 was
greater with ibrutinib compared with ofatumumab for domains
including global health status, physical functioning, fatigue, dys-
pnea, and constipation, whereas the improvement was greater with
ofatumumab for role functioning, social functioning, and appetite
loss. When considering the threshold for clinically meaningful
improvement, only dyspnea was improved with ibrutinib (mean
change, 11.0) and appetite loss with ofatumumab (mean
change, 13.0). Notably, comparative data between treatment
groups are limited due to the ofatumumab arm ﬁxed duration of
treatment (maximum 6 months) and relatively short PFS (median,8.1 months),14 but the overall effects of ibrutinib on QoL reﬂect
clinically meaningful gains that were sustained throughout the 60
weeks of follow-up. Irrespective of this disparity in drug exposure
time, the majority of positive ibrutinib beneﬁts were also observed
at the time of the primary analysis when treatment durations were
comparable.14 For safety and medical resource utilization data, this
imbalance in follow-up would generally favor ofatumumab. Despite
this, medical resource utilization as a prespeciﬁed exploratory
endpoint, including hospitalizations in the ﬁrst 30 days and growth
factor usage after day 30, was higher in the ofatumumab group
versus the ibrutinib group. Cost implications were not analyzed,
although one recent real-world analysis of front line CLL treatment
showed reduced medical resource utilization and reduced costs of
care are incurred with ibrutinib compared with chemo-
immunotherapy.28 That analysis did not evaluate pharmacy costs,
and it remains unknown how these will contribute to the balance of
costs for ibrutinib versus chemoimmunotherapy options. Such
evaluations will be of further interest in the real-world setting.
No new safety signals were identiﬁed in this study versus earlier
phase II studies,12 and new events of diarrhea, certain infections,
and cytopenias, including grade  3 events, were observed less
frequently over time. These data suggest that, except for the
appearance of grade 3 hypertension, the likelihood of new onset
treatment-emergent AEs may be reduced with long-term ibrutinib
therapy.
Conclusion
Clinical data describing psycho-oncologic endpoints in studies
of patients with CLL treated with new small targeted molecules
or biologics are sparse. These novel RESONATE ﬁndings are
among the ﬁrst randomized data to assess multiple measures of
overall patient well-being with treatment, including PROs, disease
burden, hematologic function, and beneﬁts to patients with re-
gard to disease management and reduced requirement for sup-
portive care. A survival beneﬁt with ibrutinib, together with
sustained improvements in hematologic endpoints and patient-
reported outcomes, suggest that ibrutinib can improve QoL
while prolonging survival.
Clinical Practice Points
 Complications associated with CLL and toxicities of therapy can
profoundly affect QoL and patient well-being.
 These analyses of RESONATE are the ﬁrst to show signiﬁcant
psycho-oncologic improvements with ibrutinib in R/R CLL, in
addition to the known beneﬁts of longer PFS, OS, and improved
ORR compared with anti-CD20 therapy.
 Sustained hematologic improvement, clinically meaningful
improvement in fatigue and overall QoL, and fewer early hos-
pitalizations were observed with ibrutinib compared with ofa-
tumumab while maintaining a reduction in disease burden.
 No new safety signals with ibrutinib were identiﬁed in this study,
and the onset of treatment-emergent AEs decreased over time.
 Hematologic function, QoL, and overall patient well-being are
a vital part of medical decision-making in addition to the
clinical beneﬁts of prolonged survival in patients with R/R
CLL/SLL.Clinical Lymphoma, Myeloma & Leukemia December 2018 - 811
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813.eSupplemental Methods
Sustained hematologic improvement in cytopenias were deﬁned
as hemoglobin > 11 g/dL or  50% increase over baseline  11 g/
dL, platelet counts >100  109/L or  50% increase over
baseline  100  109/L, and absolute neutrophil count >1.5 
109/L or  50% increase over baseline  1.5  109/L, sustained
for  56 days without blood transfusions or growth factors.
The effect of ibrutinib versus ofatumumab on white blood cell
count differential and lymphocyte subsets (B cells, T cells, nat-
ural killer cells) was also evaluated over time. B cells
(CD45bright, SSClow, CD3, CD19þ), NK cells
(CD45bright, SSClow, CD3, CD16þ/CD56þ), T cells
(CD45bright, SSClow, CD3þ,  CD4 or CD8), and regulatory
T cells (CD45bright, SSClow, CD3þ, CD4þ, CD127,
CD25bright & FoxP3þ) were determined by immunoﬂuores-
cence. Regulatory T cells were assessed from a subset of 48 pa-
tients, representing detected regulatory T cells from available
samples at each of the various time points. CD5 immunostaining
was not performed.1 - Clinical Lymphoma, Myeloma & Leukemia December 2018Statistical Analysis
Descriptive statistics were used to summarize ﬁndings. Unless
speciﬁed otherwise, the overall 2-sided signiﬁcance level of .05 was
used as a reference for each statistical comparison without adjusting
for multiplicity. Patients with available data were analyzed according
to the treatment to which they were randomized for baseline
characteristics and efﬁcacy endpoints, whereas those who received 
1 dose of study drug comprised the safety population.
The proportion of patients achieving sustained hematologic
improvement was compared between treatment arms using the c2
test. Median absolute values for lymphocyte subsets were used due to
chronic lymphocytic leukemia-related non-normal distributions.
Patient-reported outcome changes in total score were summa-
rized from baseline to each post-baseline time point with odds ratio
(> 1.0 favoring the ibrutinib arm for improvement) assessed be-
tween treatment arms. No imputation of missing values was per-
formed. Descriptive statistics were conducted at each scheduled
post-baseline assessment by treatment arm.
Supplemental Figure 1 Effect of Ibrutinib Versus Ofatumumab Over Time on White Blood Cell Count Differential (A), Median ALC (B),
and Percent Change From Baseline in Median ALC (C). ULN and LLN (3 109/L) for ALC: 0.91 to 4.28 for
Patients < 59 Years (Ibrutinib, n [ 41; Ofatumumab, n [ 35) and 0.8 to 3.00 for Patients ‡ 59 Years
(Ibrutinib, n [ 152; Ofatumumab, n [ 155)
Abbreviations: ALC ¼ absolute lymphocyte count; ANC ¼ absolute neutrophil count; LLN ¼ lower limit of normal; ULN ¼ upper limit of normal.
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Supplemental Figure 2 Percentage Over Time of CD3D (A), CD4D (B), CD8D (C), CD19D (D), and CD16/56D (E) cells
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Supplemental Figure 3 Effect of Ibrutinib on Tregs Quantiﬁed by Absolute Count by Flow Cytometric Staining (A) and Percentage (B).
ULN and LLN (3 109/L): 0.025 to 0.06; Shown by Dashed Lines
P < .05, signiﬁcantly different compared with baseline, with a paired t test. P < .01, signiﬁcantly different compared with baseline, with a paired t test.
Abbreviations: LLN ¼ lower limit of normal; Tregs ¼ regulatory T cells; ULN ¼ upper limit of normal.
Supplemental Figure 4 Prevalence Over Time of Grade ‡ 3 Infections Reported in > 1 Patient at Any Time With Ibrutinib (n [ 59 of
195; 30%) or Ofatumumab (n [ 40 of 196; 20%). Note: Two Ofatumumab-Treated Patients had Grade ‡ 3
Infections > 6 Months (Folliculitis, Tooth Abscess), and 1 Ibrutinib-Treated Patient had Grade ‡ 3 Infections >
18 Months (Urinary Tract infection)
Jacqueline C. Barrientos et al
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Supplemental Table 1 Compliance Rates for Patient-reported
Outcomesa
Ibrutinib,
n/N (%)
Ofatumumab,
n/N (%)
FACIT-F
Baseline 165/195 (85%) 154/196 (79%)
Week 12 (day 84) 133/188 (71%) 112/171 (65%)
Week 24 (day 168) 130/178 (73%) 102/134 (76%)
Week 36 (day 252) 112/165 (68%) e
Week 48 (day 336) 60/158 (38%) e
Week 60 (day 420) 28/154 (18%) e
Week 72 (day 504) 6/152 (4%) e
EORTC QLQ-C30
Baseline 166/195 (85%) 148/196 (76%)
Week 12 (day 84) 135/188 (72%) 116/171 (68%)
Week 24 (day 168) 131/178 (74%) 107/134 (80%)
Week 36 (day 252) 112/165 (68%) e
Week 48 (day 336) 60/158 (38%) e
Week 60 (day 420) 28/154 (18%) e
Week 72 (day 504) 6/152 (4%) e
Abbreviations: EORTC QLQ-C30 ¼ European Organization for Research and Treatment of
Cancer Quality of Life Questionnaires Core 30; FACIT-F ¼ Functional Assessment of Chronic
Illness Therapy-Fatigue.
aData for ofatumumab beyond 24 weeks were limited due to the 24-week ofatumumab therapy
and allowance of new treatments including crossover to ibrutinib following progression.
Supplemental Table 2 EORTC QLQ-C30 Domains at Baseline and Week 24
Mean ± SD
Ibrutinib (n [ 195) Ofatumumab (n [ 196)
Baseline
(n [ 118)a
Week 24
(n [ 132) D
Baseline
(n [ 89)a
Week 24
(n [ 107) D
Global health statusb 59.8  24.9 68.3  21.3 9.0  24.1 64.9  22.7 69.5  22.1 5.8  21.5
Role functioning 72.9  31.0 75.8  26.8 4.0  28.2 72.3  30.4 76.3  28.0 6.4  27.1
Emotional functioning 76.9  21.1 78.7  23.9 2.4  19.4 80.3  19.3 81.3  22.1 2.6  16.2
Physical functioning 75.6  23.6 80.6  20.5 6.4  18.0 81.4  20.4 82.0  20.2 1.7  15.7
Cognitive functioning 82.2  21.3 82.1  21.0 0.6  16.2 86.1  20.0 82.6  20.7 3.0  16.8
Social functioning 74.0  28.3 80.2  25.1 7.5  25.4 75.7  27.3 82.4  21.5 8.1  20.6
Fatiguec 35.7  27.8 28.7  24.7 8.1  22.8 31.2  25.8 27.9  24.8 4.5  23.4
Nausea/vomitingc 4.5  12.8 6.3  15.8 0.6  13.4 4.5  8.6 3.4  8.5 1.5  9.9
Pain scorec 19.1  26.8 18.8  26.2 0.7  23.7 14.0  22.2 16.0  24.7 0.2  22.5
Dyspneac 26.3  29.5 15.7  22.7 11  26.5 23.6  28.1 15.9  24.4 9.0  27.0
Insomniac 26.3  31.4 21.7  29.7 5.6  27.7 27.7  27.6 21.8  26.7 6.0  23.9
Appetite lossc 17.2  24.9 10.1  22.5 8.5  27.3 22.5  29.2 10.0  18.4 13.0  26.8
Constipationc 11.9  23.7 8.8  22.5 4.5  25.8 8.6  19.2 7.8  18.6 0.4  22.8
Diarrheac 9.6  20.0 15.2  27.4 5.1  29.8 10.1  22.1 10.9  22.8 0.4  18.5
Financial difﬁcultiesc 20.1  30.2 18.2  27.1 3.1  25.0 15.0  28.4 15.6  26.4 0.7  22.5
Abbreviations: EORTC QLQ-C30 ¼ European Organization for Research and Treatment of Cancer Quality of Life Questionnaires Core 30; SD ¼ standard deviation.
aIncludes patients with assessment at both baseline and week 24.
bWith ibrutinib, n ¼ 117 at baseline and n ¼ 131 at week 24.
cNegative change is an improvement, for all others a positive change is an improvement.
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Supplemental Table 3 Peak ALC in All Patients Treated With
Ibrutinib at Any Time
Baseline
ALC 3 109/L
Post-baseline Peak ALC 3 109/L, n (%)
< 50 50-100 100-400 ‡ 400
< 50 (n ¼ 119) 68 (57.1) 25 (21.0) 25 (21.0) 1 (0.8)
50-100 (n ¼ 36) 2 (5.6) 10 (27.8) 24 (66.7) 0 (0.0)
 100 (n ¼ 37) 1 (2.7) 1 (2.7) 30 (81.1) 5 (13.5)
Total 71 (2.7) 36 (18.8) 79 (41.1) 6 (3.1)
Abbreviation: ALC ¼ absolute lymphocyte count.
Supplemental Table 4 Patient Data for Those Experiencing MHa
MH Event
Grade 4 Subdural
Hematoma
Grade 2 Bilateral
Subdural Hematoma
Grade 3 Post-procedural
Hemorrhage
Grade 3 Spontaneous
Hematoma (in Psoas)
Start of MH, day 321 310 18 508
Use of AC/AP None reported Heparin, enoxaparin None reported Enoxaparin, clopidogrel
Platelet count 219  109/L (central; day 330);
140  109/L (local; day 321)
151  109/L (central; day 317);
64  109/L (local; day 310)
127  109/L (central; day 16);
105  109/L (local; day 19)
217  109/L (central)
Coagulation testing PT 15.1 sec (11.4-14.0);
day 323
PT 11.3 sec and PTT 29.3 sec
(both within normal limits);
day 310
PT 10.3 sec and PTT 21.3 sec
(both within normal limits);
day 19
Available from screening only,
within normal limits
Inciting events None reported None reported Post-procedural bleeding
(removal of skin lesion),
related to ibrutinib
None reportedb
Contributing AEs, other
bleeding AEs
Grade 1 thrombocytopenia Grade 1 petechiae None reported Grade 1 right hand hematoma
History of bleeding Increased tendency to bruise
(Grade 1, ongoing)
None reported None reported None reported
Abbreviations: AC ¼ anticoagulant; AE ¼ adverse event; AP ¼ antiplatelet; MH ¼ major hemorrhage; PT ¼ prothrombin time; PTT ¼ partial thromboplastin time.
aAll 4 events deemed possibly related or related to ibrutinib.
bGrade 3 fall and grade 3 cranial laceration reported on study day 489, unclear if events were contributing AEs.
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Supplemental Table 5 Adverse Events That Led to D/C of Study Drug
Preferred Term
Study Day for
Drug D/C
Investigator Response
at Time of D/C
Time to
Progression, mos
Time to Death/Last
Known Alive, mos
Ibrutinib (n ¼ 23 patients)
Sepsis 6 NA 0.3 0.3
Neutropenic sepsis 23 NA 1.1 1.1
Neutropenia 36 SD 9.4 11.3
Chronic obstructive pulmonary disease 53 PRL NA 14.6
Pneumonia 55 NA 4.0 4.0
Sepsis 57 NA 2.0 2.0
Pneumonia 69 PRL 2.4 2.4
Pneumocystis jirovecii pneumonia 73 PR 6.7 6.7
Diarrhea 79 SD 4.5 19.0
Lung adenocarcinoma metastatic 88 PRL 2.7 14.3
Gastrointestinal carcinoma 108 SD 5.8 5.8
Pneumonia 177 SD 6.0 6.0
Cardiac arrest 182 PR 6.0 6.0
Atrial ﬁbrillation 229 PD 8.2 16.9
Pneumonia 249 PR 10.8 14.4
Pneumonia 275 SD 9.6 9.6
Myositis 291 SD 13.1 15.0
Subdural hematoma 310 PD 10.7 19.4
Arrhythmiaa 313 PD 9.9 10.8
Richter syndromea 313 PD 9.9 10.8
Fatigueb 316 PR 13.4 15.5
Weight decreasedb 316 PR 13.4 15.5
Pneumonia 327 PR 11.3 11.3
Sudden death 366 SD 12.1 12.1
Transient ischemic attack 664 PR 21.7 22.2
Ofatumumab (n ¼ 16 patients)
Infusion related reaction 10 NA 13.4 16.7
Acute myocardial infarction 11 NA 5.9 14.5
Febrile neutropenia 20 PD 0.9 6.9
Nocardiosis 21 NE 3.3 3.3
Bacteremia 29 NA 1.3 1.3
Upper respiratory tract infection 29 NA 1.6 1.6
Pneumonia 30 NA 1.8 1.8
Pneumonia 37 NA 1.7 1.7
Metastatic squamous cell carcinoma 49 NA 3.2 3.2
Herpes zoster 53 NA 8.4 9.7
Inﬂuenza 76 NE 3.2 3.2
Pyrexia 94 SD 3.6 3.6
Squamous cell carcinoma 107 SD 4.2 4.2
Pneumonia 112 SD 3.9 3.9
Rash erythematous 141 PR 8.3 9.1
Pneumonia 142 SD 5.5 6.9
Abbreviations: D/C ¼ discontinuation; NA ¼ not assessed; NE ¼ not evaluable; PR ¼ partial response; PRL ¼ PR with lymphocytosis; SD ¼ stable disease.
aOne patient had 2 adverse events that led to D/C (arrhythmia, Richter syndrome).
bOne patient had 2 adverse events that led to D/C (fatigue, weight decreased).
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